Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 8:55 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1201–1224 of 2,516 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Sequence Clear all

Conditions: Critical Illness, Hypoxia, Respiratory Failure
Interventions: End-tidal oxygen monitor; Device
Lead sponsor: Sydney Local Health District; Government
Eligibility: 18 Years and older
Enrollment: 1,400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 3
States / cities: Minneapolis, Minnesota • Albuquerque, New Mexico • The Bronx, New York

Conditions: Rheumatoid Arthritis (RA)
Interventions: MTX; Drug
Lead sponsor: Antares Pharma Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 1
States / cities: Duncansville, Pennsylvania

Conditions: Healthy
Interventions: Ad26.Mos.HIV, Clade C gp140, Placebo; Biological · Drug
Lead sponsor: Janssen Vaccines & Prevention B.V.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Psoriasis
Interventions: BMS-986165, Cyclosporine; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Obstetric Labour, Premature
Interventions: Retosiban 100 mg, Retosiban 800 mg, Placebo, Moxifloxacin 400 mg; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Myelodysplastic Syndromes, Acute Myeloid Leukemia, Myelodysplastic Syndrome/Neoplasm, Chronic Myelomonocytic Leukemia
Interventions: Azacitidine, ASTX030 (cedazuridine + azacitidine), Cedazuridine, Venetoclax; Drug
Lead sponsor: Taiho Oncology, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 316 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 24
States / cities: Los Angeles, California • Orange, California • New Haven, Connecticut + 18 more

Conditions: Cancer
Interventions: RNA sequencing, Transcriptome analysis, target drug with the score above 0,1, target drug with the score equal or below 0,1, non-target drug, palliative care; Other · Drug
Lead sponsor: OmicsWay Corp.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Walnut, California

Conditions: Pharmacokinetics, Pharmacodynamics, Insulin Aspart
Interventions: I004, NovoLog; Drug
Lead sponsor: Amphastar Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 62 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Healthy Participants
Interventions: AZD4144- Part A, Placebo- Part A, AZD4144- Part B, Placebo- Part B, Rosuvastatin and Furosemide- Part C, Rosuvastatin, Furosemide, and AZD4144 Part C; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 91 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 2
States / cities: Glendale, California • Brooklyn, Maryland

Conditions: B-cell Acute Lymphoblastic Leukemia
Interventions: NGS-MRD, Myeloablative allogeneic HCT with a non-TBI conditioning regimen; Diagnostic Test · Drug
Lead sponsor: Pediatric Transplantation & Cellular Therapy Consortium; Other
Eligibility: 1 Year to 25 Years
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 24
States / cities: Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 19 more

Conditions: Autism Spectrum Disorder
Interventions: Mounted Human-equine Interaction, Unmounted Human-equine Interaction, No-Horse Control; Behavioral
Lead sponsor: Colorado State University; Other
Eligibility: 6 Years to 16 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Smoking, Endothelial Dysfunction
Interventions: Charcoal hookah, E-coal hookah, Cigarette, Carbon Monoxide inhalation, Room Air inhalation, vitamin C, tadalafil; Other · Drug
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 21 Years to 49 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Relative Bioavailability
Interventions: BDA MDI 160/180 mcg, Pulmicort Flexhaler 180 mcg; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 11 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Cystic Fibrosis
Interventions: VX-118; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Healthy Volunteers
Interventions: RO7049389, Pitavastatin; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Daytona Beach, Florida

Conditions: Pancreatic Cancer
Interventions: PEGPH20, Cetuximab, DW & DCE-MRI, blood draws; Drug · Device · Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: Aqueous Deficient Dry Eye, Meibomium Gland Dysfunction
Interventions: Subjective Questionnaire, Measurement with wavefront sensor (right eye, then left eye), Instill Saline Drop; Behavioral · Procedure · Drug
Lead sponsor: University of Rochester; Other
Eligibility: 20 Years to 65 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Mucociliary Clearance
Interventions: HFO-1234ze(E), HFA-134a; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 4
States / cities: Kansas City, Kansas • Baltimore, Maryland • Chapel Hill, North Carolina + 1 more

Conditions: Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis
Interventions: CCX168; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Healthy
Interventions: Tramadol HCl, Moxifloxacin 400 mg, Tramadol HCl Placebo, Moxifloxacin Placebo; Drug
Lead sponsor: Janssen Scientific Affairs, LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 68 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Gambling Disorder, Gambling Addiction, Gambling Problem, Gambling
Interventions: Active Low-Intensity Focused Ultrasound (LIFU), Sham Low-Intensity Focused Ultrasound (LIFU); Device
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years to 60 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2029
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Chronic Pain, Back Pain, Neck Pain, Opioid Misuse
Interventions: Tizanidine, MI-Opioid Taper, Placebo, Enhanced Usual Care; Drug · Behavioral
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 375 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 4
States / cities: Stanford, California • Kansas City, Kansas • Boston, Massachusetts + 1 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: UMEC/VI, TIO/OLO, Albuterol/salbutamol; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years and older
Enrollment: 236 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 9
States / cities: Clearwater, Florida • Orlando, Florida • St Louis, Missouri + 6 more

Conditions: Healthy Volunteers
Interventions: Zanubrutinib; Drug
Lead sponsor: BeiGene; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 58 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Dallas, Texas

Search by objective public record fields.

End-Tidal Oxygen for Intubation in the Emergency Department

Comparison of Methotrexate (MTX) and the VIBEX™ MTX Device

Safety, Tolerability and Immunogenicity Study of Different Vaccine Schedules With Ad26.Mos.HIV and Clade C Glycoprotein (gp)140 in Healthy Human Immunodeficiency Virus (HIV)-Uninfected Adults

An Investigational Study of Cyclosporine on Experimental Medication BMS-986165 in Healthy Male Participants

This Study Will Investigate the Effect of Single Oral Doses of Retosiban on Cardiac Repolarization, With Moxifloxacin as a Positive Control in Healthy Volunteers.

A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)

Identification of Molecular Biomarkers for Cancer Target Therapy Efficacy

Comparison of the Pharmacokinetics (PK) and Pharmacodynamics (PD) Biosimilarity of Proposed Biosimilar/Interchangeable Rapid-Acting Insulin Aspart (I004) and NovoLog® After Single-Dose Subcutaneous Administration to Healthy Volunteers

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4144 as Well as the Impact of AZD4144 on the Pharmacokinetics of Rosuvastatin and Furosemide in Healthy Participants

The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL

Effects of Mounted vs Unmounted Human-Equine Interaction on Autistic Youth

Hookah Smoking, Carbon Monoxide, and Coronary Endothelial Function

A Study to Compare the Pharmacokinetics of Budesonide Delivered by PT027 Compared With Pulmicort Flexhaler (ELBRUS)

A Study to Evaluate the Relative Bioavailability and Food Effect of a VX-118 Tablet Formulation

A Study to Investigate the Effect of RO7049389 on the Pharmacokinetics of Pitavastatin in Healthy Volunteers

Two Stage Study Of Single Dose PEGPH20 And Cetuximab In Patients With Pancreatic Adenocarcinoma Prior To Surgical Resection

Non-invasive Tear Film Dynamic Measurements in Normal, MGD and ADDE Subjects After Saline Instillation

Study to Assess Effect of Next-Generation Propellant MDI on Mucociliary Clearance Vs. HFA Propellant MDI in Healthy Participants

A Study in Healthy Volunteers to Evaluate the Pharmacokinetic Food Effect and Cardiac Safety of CCX168

Study to Evaluate the Effects of Tramadol Hydrochloride on Cardiac Repolarization in Healthy Participants

Low-Intensity Focused Ultrasound for Gambling Disorder

CARES (Comprehensive Analgesic, Recovery, and Education Support) for Surgery Trial

An Efficacy Study of Umeclidinium/Vilanterol With Tiotropium/Olodaterol in COPD Patients

Bioequivalence of a Zanubrutinib Tablet Compared to Capsules in Healthy Adult Participants